Sex differences in autoimmune disease from a pathological perspective.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic concepts and broad epidemiological trends without new human data or systematic review methodology.
PubMed 18688037 · doi:10.2353/ajpath.2008.071008
What was done
Narrative review synthesizing epidemiological trends and immunological mechanisms to evaluate sex and age differences in autoimmune disease pathogenesis, progression, and phenotype.
What was found
The abstract reports that autoimmune diseases affect approximately 8% of the population, with women comprising 78% of affected individuals. Male-predominant autoimmune diseases typically manifest clinically before age 50 and are characterized by acute Th1-driven inflammation and autoantibodies. Female-predominant conditions presenting acutely (such as Graves' disease and systemic lupus erythematosus) are antibody-mediated, whereas female-predominant conditions presenting after age 50 show chronic Th2-mediated fibrotic pathology, with Th17 responses contributing to neutrophil inflammation and fibrosis. No quantitative effect estimates or statistical comparisons were provided in the abstract.
Why it matters
This framework links sex differences in autoimmunity to an acute-to-chronic pathological progression model, explaining divergent clinical phenotypes and age-of-onset distributions between men and women.
Limits
As a narrative review, it presents conceptual and mechanistic models without systematic review methodology, meta-analytic pooling, or new empirical patient data. The abstract provides no specific sample sizes or study inclusion numbers.
Cited by
- supports Approximately 80% of autoimmune conditions occur in women.